ARHGAP26 and chronic myelogenous leukemia, BCR-ABL1 positive: Our results demonstrate that the functional polymorphism in the 3′UTR of the tumor suppressor ARHGAP26 creates an illegitimate binding site for miR-18a-3p, which may affect protein levels and contribute to an increased risk of CML.